The single arm, phase 2 ABACUS-trial with neo-adjuvant atezolizumab in patients with MIBC found that FAP expression remained high in relapsing tumours whereas a decrease was seen in responders, suggesting that FAP is linked to resistance to therapy [11]. The gene discussed is FAP; the disease is neoplasm.